简化CT反应标准评估胰腺癌新辅助治疗后血管受累与生存的关系
回顾性分析57例接受新辅助治疗(NAT)后达到R0切除的胰腺导管腺癌(PDAC)患者,由两名阅片者独立评估NAT后整体、动脉和静脉影像反应(改善、相似或恶化)。结果显示,NAT后影像反应改善与相似的患者中位总生存期无显著差异(55.7个月 vs 53.9个月,p=0.859),仅术后CA19-9水平与总生存期和无进展生存期相关。
要点
- NAT后CT影像反应改善或相似不能预测R0切除后PDAC患者的生存。
- 仅术后CA19-9水平与OS(p=0.002)和PFS(p=0.005)独立相关。
- 基于血管受累的简化CT评分系统在预测生存方面价值有限。
关键影像表现/征象
- NAT后39/57(68.4%)患者整体影像反应为改善,18/57(31.6%)为相似。
- 未报告动脉或静脉影像反应的具体分布数据。
诊断标准与关键数值
- 影像反应定义为基于CT的整体、动脉和静脉反应,分为改善、相似或恶化。
- 改善组中位OS为55.7个月(95% CI 33.4-未达到),相似组为53.9个月(95% CI 14.3-未达到),p=0.859。
- 术后CA19-9水平与OS(p=0.002)和PFS(p=0.005)相关。
临床应用与阅片要点
- NAT后CT评估血管受累变化可能不应作为生存预测的主要依据。
- 术后CA19-9水平对预后评估有重要价值,应结合影像和实验室指标综合判断。
- 简化影像评分系统在临床决策中的效用需进一步验证。
局限性
- 回顾性单中心研究,样本量较小(57例)。
- 未报告动脉和静脉影像反应的具体数据。
- 仅纳入R0切除患者,存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate if a simplified image based scoring system assessing treatment response after neoadjuvant therapy (NAT) can predict survival in patients with pancreatic ductal adenocarcinoma (PDAC) who achieved subsequent R0 resection.
METHODS: Retrospective analysis of 57 PDAC patients (male = 29, 51%) with mean age of 64 at diagnosis (range 42-79) who received NAT and R0 resection. Post-NAT overall, arterial and venous imaging response was characterized as improved, similar, or worse by 2 readers independently followed by consensus review. Kaplan-Meier Analysis was performed to compare overall survival (OS) with post-NAT overall imaging response. A Multivariable Cox proportional hazards analysis was performed to evaluate the association of the following variables with OS: overall, arterial and venous radiology response, clinical staging, postoperative CA19-9, and patient age.
RESULTS: At study conclusion, 30/57 patients were deceased (53%), 26/57 (46%) alive, and 1 patient unknown. Post-NAT, 39/57 (68.4%) had overall improved disease and 18/57 (31.6%) had similar disease. The median OS was 55.7 months (95% CI 33.4-not reached, NR) for those with improved disease vs. 53.9 months (95% CI 14.3-NR) with similar disease (p = 0.859) after NAT. Among all clinical parameters, only post-operative CA 19-9 level was associated with OS (p = 0.002) and PFS (p = 0.005), respectively.
CONCLUSION: Pancreatic cancer patients who underwent R0 resection showed no difference in survival when comparing those with similar vs improved disease on post-NAT imaging.
引用
- Guo Y, Czeyda-Pommersheim F, Miccio JA, et al. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdom Radiol (NY). 2021. PMID: 34557934. doi:10.1007/s00261-021-03284-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。